149 reports of this reaction
2.1% of all CROMOLYN SODIUM reports
#7 most reported adverse reaction
DYSPNOEA is the #7 most commonly reported adverse reaction for CROMOLYN SODIUM, manufactured by Prestige Brands Holdings, Inc.. There are 149 FDA adverse event reports linking CROMOLYN SODIUM to DYSPNOEA. This represents approximately 2.1% of all 7,214 adverse event reports for this drug.
Patients taking CROMOLYN SODIUM who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for CROMOLYN SODIUM, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for CROMOLYN SODIUM:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 149 FDA reports for CROMOLYN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.1% of all adverse event reports for CROMOLYN SODIUM, making it a notable side effect.
If you experience dyspnoea while taking CROMOLYN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.